The Impact of Inflammatory Adhesion on the Prognosis of Colon Cancer Patients
The Impact of Tumor-associated Inflammatory Adhesion on the Prognosis of Colon Cancer Patients: a Study Based on the SEER and Chinese Multi-center Databases
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In some colon cancer patients, although adhesions between the tumor tissue and surrounding organs are found during surgery, postoperative pathology confirms that the tumor has not directly invaded the adhered organs; instead, the adhesions are caused by tumor-associated inflammation. This condition is defined as tumor-associated inflammatory adhesion.
Currently, the impact of tumor-associated inflammatory adhesion on patient prognosis is still unclear. This study aims to explore the impact of tumor-associated inflammatory adhesion on the prognosis of colon cancer patients through the Surveillance, Epidemiology, and End Results (SEER) and Chinese multi-center databases.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- The patient was pathologically diagnosed as colon adenocarcinoma by endoscopic biopsy before operation.
- All patients were considered to have tumors invading adjacent organs during surgery
- All patients underwent radical surgery.
Exclusion Criteria:
1. Patients with distant metastasis, recurrent colon cancer and pT4b CRC were excluded.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
the U.S. National Cancer Center SEER database
SEER*Stat software (version 8.4.3) collected 17 registries cohort data on colon cancer patients between 2010 and 2019.
|
This was a retrospective study and no patient intervention was performed.
|
|
Chinese multi-center database
Chinese multi-center database includes patients from January 2010 to December 2021 at 3 institutions.
|
This was a retrospective study and no patient intervention was performed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival time (OS)
Time Frame: up to 10 years
|
OS, defined as the time from the first diagnosis to death from any cause or the last follow-up for surviving patients
|
up to 10 years
|
|
Cancer-specific survival time (CSS)
Time Frame: up to 10 years
|
CSS refers to the duration from diagnosis of a tumor until the patient succumbs to the tumor, excluding deaths from other causes.
|
up to 10 years
|
|
Recurrence free survival time (RFS)
Time Frame: up to 10 years
|
RFS is the time from the time a patient achieved R0 resection after surgery to the time of recurrence or the end of follow-up.
|
up to 10 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCC3650
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.